225 related articles for article (PubMed ID: 37243127)
21. A Kinome-Wide Small Interfering RNA Screen Identifies Proviral and Antiviral Host Factors in Severe Acute Respiratory Syndrome Coronavirus Replication, Including Double-Stranded RNA-Activated Protein Kinase and Early Secretory Pathway Proteins.
de Wilde AH; Wannee KF; Scholte FE; Goeman JJ; Ten Dijke P; Snijder EJ; Kikkert M; van Hemert MJ
J Virol; 2015 Aug; 89(16):8318-33. PubMed ID: 26041291
[TBL] [Abstract][Full Text] [Related]
22. Mechanistic Aspects of Medicinal Plants and Secondary Metabolites against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Malekmohammad K; Rafieian-Kopaei M
Curr Pharm Des; 2021; 27(38):3996-4007. PubMed ID: 34225607
[TBL] [Abstract][Full Text] [Related]
23. Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and influenza virus.
Vitner EB; Achdout H; Avraham R; Politi B; Cherry L; Tamir H; Yahalom-Ronen Y; Paran N; Melamed S; Erez N; Israely T
J Biol Chem; 2021; 296():100470. PubMed ID: 33639165
[TBL] [Abstract][Full Text] [Related]
24. Clomipramine inhibits dynamin GTPase activity by L-α-phosphatidyl-L-serine stimulation.
Miyoshi H; Otomo M; Takahashi K
J Biochem; 2023 Jul; 174(3):267-272. PubMed ID: 37137298
[TBL] [Abstract][Full Text] [Related]
25. A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease.
Mandour YM; Zlotos DP; Alaraby Salem M
J Biomol Struct Dyn; 2022 Mar; 40(5):2327-2338. PubMed ID: 33094680
[TBL] [Abstract][Full Text] [Related]
26. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M
mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634
[TBL] [Abstract][Full Text] [Related]
27. Key genetic elements, single and in clusters, underlying geographically dependent SARS-CoV-2 genetic adaptation and their impact on binding affinity for drugs and immune control.
Salpini R; Alkhatib M; Costa G; Piermatteo L; Ambrosio FA; Di Maio VC; Scutari R; Duca L; Berno G; Fabeni L; Alcaro S; Ceccherini-Silberstein F; Artese A; Svicher V
J Antimicrob Chemother; 2021 Jan; 76(2):396-412. PubMed ID: 33254234
[TBL] [Abstract][Full Text] [Related]
28. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
29. Antiviral drugs targeting endosomal membrane proteins inhibit distant animal and human pathogenic viruses.
Galindo I; Garaigorta U; Lasala F; Cuesta-Geijo MA; Bueno P; Gil C; Delgado R; Gastaminza P; Alonso C
Antiviral Res; 2021 Feb; 186():104990. PubMed ID: 33249093
[TBL] [Abstract][Full Text] [Related]
30. Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2.
Patil AM; Göthert JR; Khairnar V
Cell Physiol Biochem; 2020 Aug; 54(4):767-790. PubMed ID: 32830930
[TBL] [Abstract][Full Text] [Related]
31. Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors.
Park SB; Irvin P; Hu Z; Khan M; Hu X; Zeng Q; Chen C; Xu M; Leek M; Zang R; Case JB; Zheng W; Ding S; Liang TJ
mBio; 2022 Feb; 13(1):e0323821. PubMed ID: 35012356
[TBL] [Abstract][Full Text] [Related]
32. Recent advances in potential drug therapies combating COVID-19 and related coronaviruses-A perspective.
Nile SH; Nile A; Jalde S; Kai G
Food Chem Toxicol; 2021 Aug; 154():112333. PubMed ID: 34118347
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment.
Jung LS; Gund TM; Narayan M
Protein J; 2020 Dec; 39(6):619-630. PubMed ID: 33185784
[TBL] [Abstract][Full Text] [Related]
34. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry.
Gurard-Levin ZA; Liu C; Jekle A; Jaisinghani R; Ren S; Vandyck K; Jochmans D; Leyssen P; Neyts J; Blatt LM; Beigelman L; Symons JA; Raboisson P; Scholle MD; Deval J
Antiviral Res; 2020 Oct; 182():104924. PubMed ID: 32896566
[TBL] [Abstract][Full Text] [Related]
36. Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19.
Yang N; Shen HM
Int J Biol Sci; 2020; 16(10):1724-1731. PubMed ID: 32226290
[TBL] [Abstract][Full Text] [Related]
37. Kinetic Characterization and Inhibitor Screening for the Proteases Leading to Identification of Drugs against SARS-CoV-2.
Kuo CJ; Chao TL; Kao HC; Tsai YM; Liu YK; Wang LH; Hsieh MC; Chang SY; Liang PH
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33526482
[TBL] [Abstract][Full Text] [Related]
38. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
39. Inhibitors of Anti-apoptotic Bcl-2 Family Proteins Exhibit Potent and Broad-Spectrum Anti-mammarenavirus Activity via Cell Cycle Arrest at G0/G1 Phase.
Kim YJ; Witwit H; Cubitt B; de la Torre JC
J Virol; 2021 Nov; 95(24):e0139921. PubMed ID: 34586865
[TBL] [Abstract][Full Text] [Related]
40. Structure-Based Virtual Screening to Discover Potential Lead Molecules for the SARS-CoV-2 Main Protease.
Gahlawat A; Kumar N; Kumar R; Sandhu H; Singh IP; Singh S; Sjöstedt A; Garg P
J Chem Inf Model; 2020 Dec; 60(12):5781-5793. PubMed ID: 32687345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
